Verséa Ophthalmics Will Distribute Celularity’s Biovance and Biovance 3L Ocular Products in the United States

Celularity and Verséa Ophthalmics announced that the companies have entered into an exclusive United States commercialization agreement under which Verséa will distribute Celularity’s Biovance and Biovance 3L ocular products. The products are designed to support the treatment of ocular surface disease and ocular surgical applications. 

Financial terms of the agreement were not disclosed.

According to the companies, Biovance and Biovance 3L Ocular are single-layer and three-layer (3L) allografts, respectively, that are intended for use as a biological membrane covering that provides an extracellular matrix.

Biovance 3L Ocular is acellular and consists of three layers of an amniotic membrane that support treatment of advanced ocular surface disease. As a barrier membrane, it is intended to protect the underlying tissue and preserve tissue plane boundaries. Applications include corneal and conjunctival-related injuries or defects such as corneal epithelial defects, pterygium repair, fornix reconstruction, and other procedures, noted the companies.

“We are excited to partner with Verséa Ophthalmics to distribute our Biovance and Biovance 3L Ocular products in the United States," Robert J. Hariri, MD, PhD, Celularity’s CEO, Chairman, and Founder, stated in the press release. "Verséa Ophthalmics has the channel expertise in eye care necessary to reach physicians and to provide patients in need access to our innovative biomaterial technology.”

“As a corneal specialist by training, I have witnessed the transformative impact innovative tissue-based ocular therapeutic interventions can have for patients both in the clinic and surgically,” said Rob Sambursky, MD, President, Verséa Ophthalmics. “Our commercialization agreement with Celularity allows us to offer a decellularized, ringless, advanced wound healing option to drive forward innovation for ocular surface diseases.”